{"id":"tak-003","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL4303606","moleculeType":"Small molecule","molecularWeight":"407.40"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"TAK-003 contains weakened forms of all four dengue virus serotypes (DENV-1, DENV-2, DENV-3, DENV-4) designed to induce both humoral and cellular immune responses without causing disease. The vaccine primes the immune system to recognize and neutralize dengue viruses upon natural exposure, reducing the risk of symptomatic dengue infection and severe dengue disease.","oneSentence":"TAK-003 is a live attenuated tetravalent dengue vaccine that stimulates immune responses against all four dengue virus serotypes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:21.347Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of dengue fever caused by dengue virus serotypes 1, 2, 3, and 4 in endemic populations"}]},"trialDetails":[{"nctId":"NCT07047521","phase":"PHASE3","title":"A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2025-11-07","conditions":"Dengue Fever","enrollment":496},{"nctId":"NCT06579755","phase":"PHASE3","title":"A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-01-20","conditions":"Dengue Fever","enrollment":800},{"nctId":"NCT06741683","phase":"PHASE2, PHASE3","title":"A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2025-01-31","conditions":"Dengue Fever","enrollment":187},{"nctId":"NCT06060067","phase":"PHASE3","title":"A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India","status":"COMPLETED","sponsor":"Takeda","startDate":"2024-03-29","conditions":"Healthy Volunteers","enrollment":480},{"nctId":"NCT07158190","phase":"","title":"Evaluation of T-cell Responses After Vaccination With the Attenuated Tetravalent Dengue Vaccine (Takeda).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-06-30","conditions":"Dengue","enrollment":30},{"nctId":"NCT06665035","phase":"PHASE3","title":"A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-06-16","conditions":"Dengue Fever","enrollment":212},{"nctId":"NCT06776692","phase":"","title":"Characterisation of Dengue Vaccine-induced Specific Immunity in Vaccinees With and Without Prior Exposure to Flavivirus Infections or Vaccination","status":"RECRUITING","sponsor":"IRCCS Sacro Cuore Don Calabria di Negrar","startDate":"2024-07-10","conditions":"Dengue Vaccines","enrollment":402},{"nctId":"NCT06898775","phase":"","title":"Passive Safety Surveillance Data of Dengue Vaccine, Qdenga (TAK 003) in Private Vaccination Sites in Buenos Aires, Argentina.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación Vacunar","startDate":"2023-11-01","conditions":"Dengue Vaccines","enrollment":112345},{"nctId":"NCT04313244","phase":"PHASE3","title":"Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-05-15","conditions":"Dengue Fever","enrollment":614},{"nctId":"NCT03423173","phase":"PHASE3","title":"Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-02-12","conditions":"Dengue Fever","enrollment":923},{"nctId":"NCT03342898","phase":"PHASE3","title":"Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-02-28","conditions":"Dengue","enrollment":900}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":108,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TDV"],"phase":"phase_3","status":"active","brandName":"TAK-003","genericName":"TAK-003","companyName":"Takeda","companyId":"takeda","modality":"Biologic","firstApprovalDate":"","aiSummary":"TAK-003 is a live attenuated tetravalent dengue vaccine that stimulates immune responses against all four dengue virus serotypes. Used for Prevention of dengue fever caused by dengue virus serotypes 1, 2, 3, and 4 in endemic populations.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}